Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Race To Build Zinbryta's MS Market Share Ahead Of Even More Competition

Executive Summary

New multiple sclerosis drug Zinbryta adds a European approval to its regulatory status, but is targeting a market where there are already various options for treating relapsing-remitting MS patients.

You may also be interested in...

Biogen, AbbVie Withdraw Struggling MS Drug Zinbryta Due To Safety Issues

Antibody was approved in the US with a liver safety warning while EU regulators recently limited the drug's use. Now, EMA has begun an urgent review of reports of inflammatory brain disorders related to Zinbryta.

Biogen/AbbVie MS Drug Zinbryta Approved; Faces Crowded Market, Liver Concerns

Biogen Inc. and AbbVie Inc. may have won the FDA's approval to market Zinbryta (daclizumab) as a treatment for multiple sclerosis, but the firms are facing significant barriers in marketing the drug, which is entering an already crowded field and coming to the marketplace with a black-box warning about serious adverse liver risks, limiting its sales potential.

Biogen's Zinbryta Gets EU Nod – But Where Will It Fit In?

Biogen and AbbVie Inc.'s multiple sclerosis therapy, Zinbryta (daclizumab), has been given a green light for use in Europe – but what gap can this new drug fill in a crowded therapy space?


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts